Navigation Links
CDC Recommends VEREGEN® as Therapeutic Option for External Genital Warts in the 2010 Sexually Transmitted Diseases Treatment Guidelines
Date:1/5/2011

>

Approved by the U.S. Food and Drug Administration (FDA) in October 2006, VEREGEN® is the first prescription botanical drug approved for use in the U.S., and the first new prescription treatment for EGWs in more than a decade.(5) VEREGEN® is derived from green tea leaves from the plant Camellia sinensis (L.) O Kuntze, and contains a proprietary mixture of catechins and other green tea components. The health benefits associated with green tea catechins, which comprise 85 to 95 percent of the drug substance in VEREGEN®, are attributed in part to their antioxidative, immunostimulatory and antiviral properties.(6) However, the mode of action of VEREGEN® involved in the clearance of EGWs is unknown.  Future studies are necessary to fully understand the role of catechins in human health.(7)

VEREGEN® has demonstrated to be effective in clearing both existing and newly emerging EGWs, with complete clearance in 53.6 percent of all patients treated in two pivotal, randomized, double-blind, vehicle-controlled, Phase 3 studies. VEREGEN® also demonstrated low recurrence rates (6.8%) at 12 weeks post treatment during these trials.(8)

"EGWs can be distressing for patients," said Ralph N. Landau, Ph.D., Senior Vice President, Research and Development of Nycomed US Inc. "We are pleased that experts in the field of STDs acknowledge VEREGEN® as a proven intervention for EGWs that meets the goals of treatment – complete clearance in both existing and newly emerging warts, with a low rate of recurrence."

Important Product Safety Information About VEREGEN®VEREGEN® Ointment, 15% is a medicine for skin use only (topical) for the treatment of warts on the outside of the genitals and around the outside of the anus. It is not a treatment for warts in the vagina, cervix, or inside the anus. Your doctor may recommend examination and screening tests (such as a Pap smear) to evaluate these areas.


'/>"/>
SOURCE PharmaDerm
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
2. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
5. Task Force Recommends Screening for Hearing Loss in All Newborns
6. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
7. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
8. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
9. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
10. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
11. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)...  Makindus, Inc. a specialty pharmaceutical development company focused ... (EMA) has granted orphan drug designation for their lead ... "We are extremely pleased to now have orphan ... place for Europe . This complements ... United States for which orphan designation has ...
(Date:5/4/2015)... , May 4, 2015  By looking ... possible to distinguish between two very different conditions ... Theodore Henderson , MD, PhD., a ... complex cases, this study can help ... and therefore treatment options, for Post-Traumatic Stress Disorder ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3
... DIEGO, Dec. 1 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... completed preclinical study has affirmed the bioequivalence and comparable ... Pharmaceuticals, ADVENTRX,s partner for ANX-514 in South Korea, independently ... "Our independent confirmation of the bioequivalence and comparable overall ...
... , REDWOOD CITY, Calif., Dec. 1 Codexis, Inc. today ... its second agreement this year with Teva Pharmaceutical Industries Ltd., ... covers three undisclosed pharmaceutical products. Codexis announced an earlier ... agreement, Teva will use Codexis biocatalysis technology for key process ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Codexis Expands Collaboration with Teva 2
(Date:5/5/2015)... BioFit Engineered Products , a ... models from its two latest lines at NeoCon 2015, ... Chicago. Headlining the company’s exhibit will be new Pro ... as well as the unveiling of the fifth model ... Ed Metzger will deliver in-booth presentations each day of ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 With the ... clothing and enjoying the feel of warm breezes on bare ... to strategies on how to look their best in shorts, ... “More and more people are turning to laser treatments for ... aesthetician of Simply Posh Aesthetic Spa . “They're all ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 “We currently have larger ... states Marta Phillips, owner of SunGrubbies.com. “We felt it was ... to find a fashionable sun hat in an extra large size ... event.” , Fashionable derby sun hats such as the ... brim are now available in an extra large size , ...
(Date:5/5/2015)... San Francisco, Calif. (PRWEB) May 05, 2015 ... available online but these have focused primarily on personal ... the National Directory of Insurance (NDOI.com) has ... licensed insurance agents in the U.S. to present their ... public marketplace. , The result is significant and two-fold. ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 No ... The Centers for Disease Control and Prevention cite ... effects our everyday life: “Poor indoor air quality (pollution) can ... to chronic heart and lung problems and cancer.” , Toxic ... swallow them in contaminated food or water, or in some ...
Breaking Medicine News(10 mins):Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3Health News:Laser Hair Removal: Tips for Summertime Grooming 2Health News:Laser Hair Removal: Tips for Summertime Grooming 3Health News:SunGrubbies.com, a Leading Online Retailer of Sun Protection Products, Launches Their New Extra Large Size Fashion Sun Hats Collection 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 2Health News:NDOI Launch Brings Commercial Insurance Online for the First Time 3Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 3
... to reasearchers, a hormone is released into the blood after ... might be supportive in treating obesity. The reason for feeling ... hormone called PYY3-36 //which acts on the brain to produce ... report on the first human trial of PYY3-36. ...
... could be saved each year, if only everyone over the ... experts, Dr. Gregory Poland fe that universal vaccination in three ... by 40 to 50 per cent. Clearly vaccination can be ... per cent. ,Dr Poland proposes some changes to ...
... to the dimpled, 'orange peel' skin on the thighs, buttocks, ... all have a beneficial effect on the appearance of cellulite ... body's natural way of storing fat in women and occurs ... a dermatologist at the University of California, cellulite is now ...
... According to recent update, people with type 2 diabetes ... able to safely reduce their risk for heart disease ... runs counter to previous research, which showed niacin adversely ... the researchers used high doses of the medication. ...
... in lessening the symptoms of fibromyalgia.,Researchers at Pole Hospital, ... with fibromyalgia, a painful muscular condition whose causes are ... to routine sessions of graded aerobic exercise, supervised by ... of those in the exercise group rated themselves as ...
... feel, that we need to learn more about ... microwaves play an increasing role in everyday life - ... pagers, and text messengers. ,We often walk past ... other words, we are bathed in an invisible 'electrosmog', ...
Cached Medicine News:
Coat-A-Count PSA IRMA is an,immunoradiometric assay intended for the,quantitative measurement of,prostate-specific antigen (PSA) in serum,to aid in the management of prostate,cancer patient...
Stereo Smile II also includes a blank card and tests,at 60, 120, 240 and 480 sec of arc., ,Smile Test II Includes:, 1 demonstration card, 1 pair pediatric 3-D viewers, 1 pair infant 3-D v...
... and Evaluate Stereo Depth Perception ... 250 sec of arc). , ... Test (400 to 20 sec ... for Children (400 to 100 ...
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
Medicine Products: